Dietrich Stephan

Dietrich Stephan

Directeur/Membre du Conseil chez
Epistemix, Inc.

Fortune : 144 944 $ au 31/10/2026

56 ans
Consumer Services
Health Technology
Commercial Services

Profil

Dietrich A. Stephan was the founder of Amnestix, Inc. (founded 2006), serving as Director-Neurogenomics Division; Life Technologies Clinical Services Lab, Inc. (founded 2006), serving as Director & Chief Science Officer from 2007 to 2011; Lifecode, Inc. (founded 2011), serving as President, Chief Executive Officer & Director from 2011 to 2015; and NeuBase Therapeutics, Inc. (founded 2009), serving as Chief Executive Officer & Director from 2022 to 2024.
Dr. Stephan is also the founder of DiaVacs, Inc.,LifeX Holdings LLC..
Dr. Stephan currently serves as Chairman-Neuroscience Microarray Consortium at the National Institutes of Health since 2011; Independent Director at Sharp Therapeutics Corp.
since 2024; Director at FRX Growth Partners LLC; Director at Epistemix, Inc.; Member at National Institute of Health Policy; and Managing Partner at Cyto Ventures since 2018.
Former positions include President & Chief Executive Officer at Neubase Therapeutics, Inc.; Chairman-Human Genetics Department & Professor at the University of Pittsburgh; Chairman-Neurogenomics Department & Professor at Translational Genomics Research Institute; Chairman at Pendulum, Inc.; Chairman at Peptilogics, Inc. from 2016 to 2025; Director at Western Oncolytics Ltd.; Executive Director-Gene Partnership at The Children's Hospital Corp.
and Harvard Medical School; Director at Personalized Medicine Coalition, Sharp Edge Labs, Inc., iGenomX International Genomics LLC, Parabase Genomics, Inc., Ariel Precision Medicine, Inc., CereDx, Inc.; Director at Pendulum Therapeutics, Inc. from 2012 to 2018; Faculty Member at George Washington University, Arizona State University, The Johns Hopkins University, and the University of Arizona; and Chief Science Advisor at FarmaceuticalRX LLC.
Education includes undergraduate studies at Carnegie Mellon University and a doctorate from the University of Pittsburgh Graduate School of Public Health.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
0,77 %
21/05/2025 241 574 ( 0,77 % ) 144 944 $ 31/10/2026

Postes actifs de Dietrich Stephan

SociétésPosteDébut
Directeur/Membre du Conseil -
Directeur/Membre du Conseil -
National Institute of Health Policy
Corporate Officer/Principal -
Corporate Officer/Principal 26/07/2011
Cyto Ventures
Corporate Officer/Principal 01/01/2018

Anciens postes connus de Dietrich Stephan

SociétésPosteFin
Président 01/03/2025
NEUBASE THERAPEUTICS, INC. Directeur Général 16/01/2024
Directeur/Membre du Conseil 01/08/2018
Fondateur 01/04/2011
░░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░ ░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ -
Voir l'expérience en détail de Dietrich Stephan

Formation de Dietrich Stephan

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

69

Relations au 1er degré

33

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées33

Consumer Services

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Consumer Services

Consumer Services

Consumer Services

Health Services

Government

Commercial Services

Health Services

National Institute of Health Policy

Consumer Services

Commercial Services

Commercial Services

Technology Services

Consumer Services

Health Technology

Commercial Services

Health Services

Health Services

Health Technology

Process Industries

Health Technology

Process Industries

Health Technology

LifeX Holdings LLC

Cyto Ventures

Commercial Services

Pendulum, Inc.

Technology Services

  1. Bourse
  2. Insiders
  3. Dietrich Stephan
🔇